UNSPSC 51313423: Chlorpheniramine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19CLN2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S6VUP419V. Most nations, for tariff and trade purposes, schedule chlorpheniramine hydrochloride under HS 29333910. As of Q4 2014, CHLORPHENIRAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Chlorpheniramine hydrochloride bears US NLM identifiers UMLS ID C2828313 and NCI Concept Code C87465. SMILES: CN(C)CCC(C1CCC(CC1)CL)C2CCCCN2.CL.

UNSPSC 51313423 Chlorpheniramine hydrochloride is a Commodity code representing pharmaceutical products being procured by state and local health agencies, though recent activity under this specific code shows limited direct alignment with chlorpheniramine itself—instead, state and local buyers are acquiring broader categories of generic pharmaceuticals, naloxone, and drug deactivation systems through cooperative purchasing vehicles and competitive bidding. Issuing bodies span state health departments (Texas Health and Human Services Commission), multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance covering Minnesota and Oregon), and county health agencies (Seminole County, Florida). The actual scope of work involves supply agreements for generic multi-source pharmaceuticals meeting FDA compliance and current Good Manufacturing Practices standards, with vendors required to maintain relationships with authorized drug wholesalers and meet stringent insurance and regulatory documentation requirements.

Recent activity concentrates in the Southeast and Midwest, with notable solicitations from Florida, Texas, and Minnesota. The Minnesota MMCAP RFP (S1070000015802) issued January 20, 2026, with proposals due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted heavily on price competitiveness (75 percent) and compliance with cGMP and DSCSA standards. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline, structured as a two-year initial contract with one-year renewal option. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional PBM and wholesaler arrangements, signaling exploratory procurement planning rather than immediate award activity.